Surety Medicine 
Mycobacterium tuberculosis bacteria - CDC image 

Mycobacterium tuberculosis,  the bacteria that causes the destructive and potentially fatal disease tuberculosis, is shown in this scanning electron microscope image.  Screening for active tuberculosis (TB) or latent tuberculosis infection (LTBI) can be accomplished with a range of diagnostic tools, including skin, blood, and sputum tests, or through chest X-ray.

                                                                                                                                                                    - CDC photo

May 2017 Surety Medicine Teleconference:

Screening for Active Tuberculosis and Latent
Tuberculosis Infection:  
TB Skin Tests vs. Alternatives

WEDNESDAY, 17 May 2017 will bring the next Surety Medicine Teleconference, at 1 pm (1300) Eastern Time.  The topic for May is "Screening for Active TB and LTBI:  TB Skin Tests vs. Alternatives.”  The presenter will be a physician from the Uniformed Services University of Health Sciences who is a researcher specializing in tropical public health.

To receive access information for attending the presentation by dial-in audio or on your computer via Defense Collaboration Services (DCS), send an email request to:



 Date           Topic                                                                                             

17 MAY 2017

Screening for Active TB or LTBI:  TB Skin tests vs. Alternatives

21 JUN 2017

Heat Stress Prevention and Management Issues
in the Surety Environment

19 JUL 2017

Syncopal Conditions:  Impacts on PRP Reliability

16 AUG 2017

Key Stakeholders in the ASAP -- Developing an Alliance
with the CMA

20 SEP 2017

Abuse, Dependence, and Substance Use Disorders: DSM-IV-TR vs. DSM-5



The 2017 BSAT Medical Support Course is scheduled for 27-30 June at the Army Medical Department Center and School, San Antonio, TX.  This course meets the education requirements of AR50-1 for Biological PRP Competent Medical Authority. 

For additional information about this four-day course, including information to attend, send an email request to:


ALERT:  FDA Simplifies Rule for Anthrax PEP


The US Food and Drug Administration (FDA) has approved the current Anthrax Vaccine Adsorbed for use in combination with antibiotic therapy after a confirmed or suspected exposure to Bacillus anthracis, the causative agent for anthrax.  The vaccine had been approved in 1970 for pre-exposure protection of those who might be exposed to the organism, but this recent approval for use in post-exposure prophylaxis (PEP) approves the use of the vaccine in combination with selected antibiotics to significantly improve the chances of survival in patients exposed to inhaled anthrax, without the previously required use of an investigational new drug (IND) protocol.

Additional information is available from the FDA at:  

ALERT:  Autoinjector Shelf Life Extension Program:  Current Information

NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM:  Many expiration date extensions for autoinjector medications expire in 2017! 
Check any auto-injector medication stores you have.  Select the link
below for additional information from the FDA.

The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labelled expiration dates, some up to 31 October 2019.  Complete FDA information related to the auto-injector shelf life extension program can be found at: .  

Information on this page also includes the latest updates (4/15/2016) on shelf life
extensions for the AtroPen (atropine), CANA (diazepam), morphine sulfate, and
pralidoxime chloride auto-injectors. 



Related programs and contacts